Switch theme
Sign up to access all valuation multiples
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
2017
35
LTM Revenue $29.3M
LTM EBITDA n/a
-$4.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Equillium has a last 12-month revenue of $29.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Equillium achieved revenue of $41.1M and an EBITDA of -$7.6M.
Equillium expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Equillium valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $36.1M | $41.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$12.1M | -$7.6M | XXX | XXX | XXX |
| EBITDA Margin | -34% | -18% | XXX | XXX | XXX |
| Net Profit | -$62.4M | -$13.3M | XXX | XXX | XXX |
| Net Margin | -173% | -32% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Equillium's stock price is $0.
Equillium has current market cap of $17.4M, and EV of -$4.8M.
See Equillium trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$4.8M | $17.4M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Equillium has market cap of $17.4M and EV of -$4.8M.
Equillium's trades at -0.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Equillium's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Equillium and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$4.8M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | XXX | XXX |
| P/E | -2.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEquillium's NTM/LTM revenue growth is -100%
Equillium's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Equillium's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Equillium's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Equillium and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 91% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 120% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Equillium acquired XXX companies to date.
Last acquisition by Equillium was XXXXXXXX, XXXXX XXXXX XXXXXX . Equillium acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Equillium founded? | Equillium was founded in 2017. |
| Where is Equillium headquartered? | Equillium is headquartered in United States of America. |
| How many employees does Equillium have? | As of today, Equillium has 35 employees. |
| Who is the CEO of Equillium? | Equillium's CEO is Mr. Bruce D. Steel. |
| Is Equillium publicy listed? | Yes, Equillium is a public company listed on NAS. |
| What is the stock symbol of Equillium? | Equillium trades under EQ ticker. |
| When did Equillium go public? | Equillium went public in 2018. |
| Who are competitors of Equillium? | Similar companies to Equillium include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Equillium? | Equillium's current market cap is $17.4M |
| What is the current revenue of Equillium? | Equillium's last 12-month revenue is $29.3M. |
| What is the current EV/Revenue multiple of Equillium? | Current revenue multiple of Equillium is -0.2x. |
| What is the current revenue growth of Equillium? | Equillium revenue growth between 2023 and 2024 was 14%. |
| Is Equillium profitable? | Yes, Equillium is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
